Aspire Biopharma (ASBP) Holdings announced the filing of a provisional patent application with the United States Patent and Trademark Office. The application, titled “A Sublingual Powder Formulation of Ondansetron and Methods of Use Thereof,” marks the first-ever sublingual powder delivery system for ondansetron-the active ingredient in Zofran. Aspire’s formulation is designed to provide rapid relief for patients suffering from nausea and vomiting induced by chemotherapy, radiation, or surgery.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASBP:
- Aspire Biopharma regains compliance with Nasdaq minimum bid price rule
- Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages
- Aspire Biopharma Raises $2 Million Through Private Financing
- Aspire Biopharma, Microsize partner for sublingual aspirin development
- Aspire files patent application for clopidogrel sublingual powder formulation